financetom
Market
financetom
/
Market
/
Sebi fines brokerage firm, Anand Rathi for violating stock broker norms
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sebi fines brokerage firm, Anand Rathi for violating stock broker norms
Nov 27, 2018 8:31 PM

Markets regulator Sebi on Tuesday fined brokerage house Anand Rathi Rs 1 lakh for violating stock broker norms by transferring funds from the client's account to own account and vice versa on several occasions.

Share Market Live

NSE

In an order, the regulator said that Anand Rathi Shares and Stock Brokers has mixed-up client's funds with its own funds and vice versa and thereby acted in contravention of Sebi (Stock Brokers and Sub-Brokers) Regulations.

The regulator had outlined strict segregation of client's funds, member account's funds and transfer of funds is permitted as an exception under specific instances.

However, the scheme of arrangement regarding transfer of money made by the Anand Rathi is not in accordance with the permissible conditions under the stock brokers norms which makes it liable for monetary penalty, Sebi noted.

Accordingly, the Securities and Exchange Board of India (Sebi) imposed a fine on the firm.

In a separate order, Sebi has levied a total penalty of Rs 5 lakh on four persons for failing to make disclosure about change in their shareholding in SMS Techsoft Ltd within the required timeline.

The persons facing penalties are Kirtikumar Rasiklal Shah, Alkaben Kirtibhai Shah, Karan Kirtibhai Shah and Kewal Kirtikumar Shah.

According to Sebi, these four persons, who were acting in concert, collectively acquired over 39 lakh shares of the company, which resulted in cumulative change in their shareholding.

However, they failed to mandatory disclosure about this as required under SAST (Substantial Acquisition of Shares & Takeovers) Regulations to the company and BSE.

First Published:Nov 28, 2018 5:31 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US STOCKS SNAPSHOT-Futures hold gains after PCE inflation data
US STOCKS SNAPSHOT-Futures hold gains after PCE inflation data
Jun 28, 2024
June 28 (Reuters) - U.S. stock index futures were steady on Friday after a key inflation reading was broadly in line with expectations in May, lifting hopes for an earlier start to policy easing. The personal consumption expenditures (PCE) price index - the Federal Reserve's preferred inflation gauge - was flat, in line with expectations. On an annual basis, PCE...
Sector Update: Financial Stocks Advance Pre-Bell Friday
Sector Update: Financial Stocks Advance Pre-Bell Friday
Jun 28, 2024
08:38 AM EDT, 06/28/2024 (MT Newswires) -- Financial stocks were advancing premarket Friday, with the Financial Select Sector SPDR Fund ( XLF ) gaining 0.4%. The Direxion Daily Financial Bull 3X Shares ( FAS ) was 1.2% higher, while its bearish counterpart Direxion Daily Financial Bear 3X Shares ( FAZ ) retreated 1% recently. Deutsche Bank ( DB ) has...
Sector Update: Energy
Sector Update: Energy
Jun 28, 2024
08:27 AM EDT, 06/28/2024 (MT Newswires) -- Energy stocks were rising premarket Friday, with the Energy Select Sector SPDR Fund (XLE) recently gaining 0.8%. The United States Oil Fund (USO) was 0.3% higher, and the United States Natural Gas Fund (UNG) advanced 1.3%. Front-month US West Texas Intermediate crude oil was up 0.5% at $82.17 per barrel at the New...
Sector Update: Health Care
Sector Update: Health Care
Jun 28, 2024
08:18 AM EDT, 06/28/2024 (MT Newswires) -- Health care stocks were trending lower pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) down 4.9% and the iShares Biotechnology ETF (IBB) unchanged. Carisma Therapeutics ( CARM ) said late Thursday that it nominated an in vivo CAR-M targeting Glypican-3 as the first development candidate under its collaboration with Moderna...
Copyright 2023-2025 - www.financetom.com All Rights Reserved